Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,145 | $2,538 | $2,607 | $2,454 |
| - Cash | $201 | $81 | $59 | $111 |
| + Debt | $2,686 | $2,582 | $2,580 | $2,593 |
| Enterprise Value | $5,629 | $5,039 | $5,127 | $4,937 |
| Revenue | $785 | $725 | $695 | $731 |
| % Growth | 8.3% | 4.2% | -4.8% | – |
| Gross Profit | $274 | $286 | $256 | $263 |
| % Margin | 34.9% | 39.5% | 36.8% | 36% |
| EBITDA | $112 | $177 | $155 | $112 |
| % Margin | 14.2% | 24.4% | 22.2% | 15.4% |
| Net Income | $2 | $22 | $12 | -$31 |
| % Margin | 0.3% | 3.1% | 1.8% | -4.3% |
| EPS Diluted | 0.008 | 0.07 | 0.038 | -0.1 |
| % Growth | -89.2% | 84.8% | 137.6% | – |
| Operating Cash Flow | $118 | $84 | $7 | $118 |
| Capital Expenditures | -$15 | -$27 | -$18 | -$23 |
| Free Cash Flow | $103 | $57 | -$11 | $95 |